Therapix Biosciences Rolls Out Cannabinoid-Based Technology for Obstructive Sleep Apnea

Therapix Biosciences Ltd. TRPX , a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that this month, the first subject was enrolled for its Phase IIa, sponsor-initiated clinical trial using the Company’s cannabinoid-based technology THX-110 for Obstructive Sleep Apnea (OSA), at Assuta Medical Center, the largest private hospital network in Israel.

Adi Zuloff-Shani, Ph.D., Chief Technology Officer of Therapix TRPX , said “We are very excited by the potential of our innovative THX-110 to potentially make a difference in OSA treatment and to improve the quality of life outcomes for patients who suffer from OSA. more at